HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.

5th Edition of Global Conference on

Addiction Medicine, Behavioral Health and Psychiatry

October 21-23, 2024 | Baltimore, Maryland, USA

GAB 2023

Thersilla Oberbarnscheidt

Speaker at Addiction Medicine, Behavioral Health and Psychiatry 2023 - Thersilla Oberbarnscheidt
University of Pittsburgh, United States
Title : In a world of deltas: Review of clinical implications of delta 8,9 and 10 THC

Abstract:

Along with the legalization of marijuana throughout the U.S., there is an increase in use of delta products as well. While these delta-THCs are widely available and advertised, little information about the effects and possible risks are broadcast to the public. Marijuana is federally classified as a Schedule 1 substance; however, the Delta drugs are not regulated. According to the Farm Bill from 2018, hemp products with less than 0.3% THC can legally be bought, sold, and grown in most states in the U.S., creating a loophole for marketing of these products. For the user this means that there is no assurance of content of the purchased product, and they bear the risk of potentially containing harmful byproducts.?

Delta-9-THC is one of the primary psychoactive cannabinoids of marijuana. Delta-9 is hemp derived and binds to the same cannabinoid receptors as marijuana. It can induce the same psychoactive effects which are euphoria, feeling “stoned”, anxiety or paranoia as well as aggression.

Delta-8-THC is commonly called “marijuana lite” or “diet weed”. Marijuana contains Delta-8 THC only in a small percentage. The sold Delta 8 product is typically made by synthetically converting CBD or Delta 9 THC into Delta 8. Delta 8 binds to the same receptors as Delta 9; Little research is available on Delta 8, but available studies are showing side effects that are comparable to marijuana ranging from paranoia, difficulties with concentration, memory, perception of time to sedation and euphoria. Concerning are reports of accidental severe intoxication, resulting in more than 2000 calls to poison control centers between January 2021 and February 2022. Several states have started to ban the recreational sales of delta-8-THC.

Delta-10-THC, however, is often reported to cause more euphoria and energy rather than sedation. Little research is available regarding its benefits and side effects, but the novelty of this substance makes it especially attractive to users. The delta-drugs are available in various forms: edibles, vaped concentrates as well as smoking bud or flower or in topical ointments. About 50% of consumers of delta-drugs also reported in surveys to use marijuana as well. It is important for mental health workers and physicians from other fields of medicine to know and understand these substances in order to be able to assess the clinical presentation correctly and to provide the effective clinical care for acute and ongoing stabilization.

This presentation is a systematic review of literature looking at the available data for Delta 8,9,10 for psychiatric and medical use. Utilized sources were PubMed, Ovid, Medline, Psych Info, EMBASE.

Audience Take Away Notes:

  • This presentation will help the audience to better understand Delta-THC drugs as they are increasingly becoming popular and widely used.
  • No matter in what field of medicine the audience works in, they will meet patients or clients who are using Deltas and will need to know how those affect their physical and mental health and how they are interacting and interfering with their prescribed medications.
  • I am hoping that the audience will become interested in this topic and further investigate. Little research is so far available.
  • This presentation will provide important information for the audience for the everyday clinical work but also raise awareness of public health concerns that are related to the increasing availability and use of deltas.
  • Delta products are increasingly available throughout the U.S. Unlike other substances, these can be purchased in local convenience stores and shops. Even bill boards along highways or commercials on tv are advertising about these products. The audience will gain competence in addressing the use of Deltas in their clients and patients.

Biography:

Thersilla Oberbarnscheidt is an Assistant Professor at the Western Psychiatric Hospital at the University of Pittsburgh where she also completed her fellowship in Addiction Psychiatry. She completed her residency at Central Michigan University in Psychiatry and her graduated Medical School from the Christian-Albrechts University in Germany as well as Yale University School of Medicine. She completed her PhD in neuroscience at the Christian-Albrechts University as well with the thesis of "The effect of phenazone in the acute migraine attack". Thersilla has a long-standing interest in the field of Addiction and has published numerous articles in the field of Addiction. Her particular interest is in Marijuana and Opioids.

Watsapp